Clinical trial · Observational
Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This non-interventional retrospective medical record review study will assess the prevalence of KRAS testing and the impact of the KRAS test result on patterns of Vectibix use in patients with metastatic colorectal cancer (mCRC) treated with Vectibix in selected European countries over 3 rounds. As the optimal use of Vectibix also requires accurate KRAS mutation testing, this study will also assess data from the laboratory that performed the KRAS test. The study will also monitor changes in the pattern of Vectibix treatment between the different rounds of the study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Other | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Round 1
- description
- 50 oncologists participate in Round 1. At least 3 medical records will be reviewed per oncologist
- interventionNames
- Other: Other
- label
- Round 2
- description
- 50 oncologists will participate in Round 2. At least 3 medical records will be reviewed per oncologist. Round 2 will occur approximately 12 months after Round 1
- interventionNames
- Other: Other
- label
- Round 3
- description
- 50 oncologists will participate in Round 3. At least 3 medical records will be reviewed per oncologist. Round 3 will occur approximately 24 months after Round 1
- interventionNames
- Other: Other
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Physician Inclusion Criteria: * Must be a practicing oncology specialist * Must treat at least 5 new or continuing patients with metastatic colorectal cancer per quarter * Must have prescribed Vectibix to treat at least 5 new or continuing patients with metastatic colorectal cancer in the past 6 months Physician Exclusion Criteria: * Must be the only oncologist sampled at the same medical centre for that round of the study * Must not have taken part in the study previously Patient Inclusion Criteria * Must have received Vectibix for the treatment of metastatic colorectal cancer during the 6-month period prior to the time when medical records are obtained * Must not have been in any experimental clinical trial at the time of receiving Vectibix * Must provide written consent to allow access to their medical records (if local laws require it) * Must not have taken part in the study before
References
Publications (1)
- BACKGROUNDHan van Krieken J, Kafatos G, Bennett J, Mineur L, Tomasek J, Rouleau E, Fabian P, De Maglio G, Garcia-Alfonso P, Aprile G, Parkar P, Downey G, Demonty G, Trojan J. Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review. BMC Cancer. 2017 Nov 28;17(1):798. doi: 10.1186/s12885-017-3740-4. PMID 29183279